Consultado el 2 de octubre de 2025: Informe de Posicionamiento Teraputico de tirzepatida (Mounjaro), AEMPS
Unlike earlier generation medications that activate only one or two pathways, Retatrutide engages the full spectrum of incretin and metabolic hormone signaling
fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss Wilding JPH, Batterham RL, Calanna S, et al
Diarrhea, which occurs in approximately 15-23% of patients taking tirzepatide (with higher rates at higher doses and in the weight management indication), can independently cause visible mucus in stool
Byetta, the first GLP-1 on the market in 2005, was used to treat diabetes, and other GLP-1s soon followed